Riverain’s imaging software cleared by FDA

The FDA has granted 510(k) clearance to Riverain Technologies’ ClearRead +Confirm software that improves the clarity of chest X-rays and reduces the time it takes radiologists to confirm the proper placement of tubes, lines and cardiac wires in the chest.

ClearRead +Confirm software received CE Mark approval in Europe last November.

ClearRead +Confirm increases portable chest X-ray readability by selectively increasing contrast and suppressing the clavicles and ribs in the image, thus removing obstacles that could obscure visibility of various tubes, lines and cardiac wires.

“ClearRead +Confirm gives radiologists a clearer view of portable chest X-ray images at a critical point in patient care, when treatment decisions depend on the confirmation of proper tube and line placement,” said Riverain’s CEO Steve Worrell. “The software saves time without sacrificing precision, benefitting physicians and patients alike.”

Recent Posts

Blog Post Archive

Blog Post Categories

Search the Blog

Newsticker


BioOhio Member Mark BioOhio Member

43North competition awards OSU student’s Genetesis $260K and People’s Choice award | Columbus Business First, October 31, 2014

New study shows combining GanedenBC30 with prebiotics provides digestive health benefits | Ganeden, October 30, 2014

Charles River acquires ChanTest for up to $54M | GEN, October 30, 2014

Ashland Specialty Ingredients launches web-based film-coatings troubleshooting tool and new pharmaceutical excipients website | PR Web, October 30, 2014

IBM and Cleveland Clinic use Watson to advance genomic research for cancer care pilot | PR Newswire, October 29, 2014

Cleveland Clinic announces Top Ten medical innovations for 2015, mobile stroke unit and Dengue vaccine top list (video) | Cleveland.com, October 29, 2014

Ampersand Capital Partners exits ChanTest investment with sale to Charles River Laboratories | PR Newswire, October 29, 2014

Camargo Pharmaceutical Services meets growing client needs with appointment of industry leader Steven Castillo as Vice President Of Drug Development | BioSpace, October 29, 2014

Scientific breakthrough at Cincinnati Children’s Hospital Medical Center could help battle cancer, ulcers | Cincinnati Business Courier, October 29, 2014

Devicor Medical Products of Sharonville, Ohio acquired by Danaher Corporation’s Leica Biosystems | Cincinnati.com, October 28, 2014

GTCR announces sale of Devicor Medical Products to Danaher Corporation’s Leica Biosystems | Business Wire, October 28, 2014

Researchers at Cincinnati Children’s Hospital Medical Center studying how to create replacement organs for people who need transplants | Cincinnati Business Courier, October 28, 2014

Juventas Therapeutics strengthens management team with new senior vice president of finance and operations, Troy Ignelzi | PR Newswire, October 28, 2014

Enable Injections signs strategic development agreement with CSL Behring to market novel drug delivery device | Philadelphia Business Journal, October 28, 2014

Ohio’s 2014 Bioproduct World Conference names Magic Dirt of Little Rock, Arkansas the Bioproduct Innovation of the Year | Wisconsin State Farmer, October 28, 2014

Ohio Soybean Council Foundation offers $36,000 in scholarships, majors include biotechnology | Ohio Soybean Council Foundation, October 28, 2014

Danaher’s Leica Biosystems division agrees to buy Devicor Medical Products, a developer of breast biopsy products | MASS Device, October 28, 2014

University Hospitals selects GenomOncology’s GO Clinical Workbench to launch their first NGS-based cancer diagnostic test | PR Newswire, October 27, 2014

INC Research of Raleigh, NC and the former Kendle location in Cincinnati, OH, plans IPO of up to $156M | Triangle Business Journal, October 27, 2014

NASA Glenn Research Center’s new office building is an example of continued commitment to Brook Park | Cleveland.com, October 27, 2014